Celgene Corporation v. Cyclacel Pharmaceuticals Inc.
1:10-cv-00348
Overview
Parties
Plaintiff
Celgene Corporation NPE (Individual / Inventor)
Represented By
11 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Counter Claimant
Cyclacel Pharmaceuticals Inc. Operating Company
Represented By
7 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 6 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 6,403,555 B1 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 6,548,479 B1 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 6,828,302 B1 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,041,639 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 16,973,199 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 19,358,200 P | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6403555
Depsipeptide and congeners thereof for use as immunosuppressants
|
Filed: 2000-12-06
Issued: 2002-06-11
|
Expired (Term Ended)
Expires: 2020-12-06
|
|
|
US6548479
Therapeutic uses of depsipeptides and congeners thereof
|
Filed: 2002-04-02
Issued: 2003-04-15
|
Expired (Term Ended)
Expires: 2022-04-02
|
|
|
US6828302
Therapeutic uses of depsipeptides and congeners thereof
|
Filed: 2003-03-27
Issued: 2004-12-07
|
Expired (Term Ended)
Expires: 2023-03-27
|
|
|
US7041639
Depsipeptide and congeners thereof for use as immunosuppressants
|
Filed: 2004-10-08
Issued: 2006-05-09
|
Expired (Term Ended)
Expires: 2024-10-08
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
33
Dispositive
0
Granted
3
Denied
0
Pending / Review
30
Motions by Category
Key Dispositive Motions & Rulings